RTI Biologics, Inc. (RTIX) Reports In-Line Q4 EPS; Guides Q1, FY13

Go back to RTI Biologics, Inc. (RTIX) Reports In-Line Q4 EPS; Guides Q1, FY13

Roth Capital Downgrades RTI Biologics (RTIX) to Neutral

February 7, 2013 3:11 PM EST

Roth Capital downgraded RTI Biologics (NASDAQ: RTIX) from Buy to Neutral with a price target of $5.00 (from $4.50) following Q4 results.

For an analyst ratings summary and ratings history on RTI Biologics click... More